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Purpose: Nonsurgical treatment of hemorrhoidal disease (HD) includes medical and instrumental techniques. We aimed 
to compare the efficacy of the most frequently used nonsurgical strategies, either alone or in combination, applied in an 
ambulatory setting. 
Methods: Patients who received nonsurgical treatment for HD by proctology appointment at the Gastroenterology De-
partment of Braga Hospital were evaluated. Isolated rubber band ligation (RBL) and a combination of RBL with a micron-
ized purified flavonoid fraction (MPFF) were the 2 most frequently used strategies. Symptoms of HD (bleeding, pruritus, 
pain at rest, pain at defecation and prolapse) were assessed at days 0, 7, and 28 by using a severity grading scale (0 to 4/5). 
A Global Symptom score was constructed to assess the overall severity and compare the overall improvements of the HD 
symptoms between the 2 most frequently used strategies.
Results: Nineteen patients underwent the combined treatment (RBL + MPFF group) and 25 the RBL treatment (RBL 
group). A comparison of the 2 treatment groups showed significant improvements in the combined treatment group in 
terms of bleeding at days 7 (P = 0.001) and 28 (P = 0.002) and in the pruritus intensity during the first week (P < 0.001). A 
trend toward clinical benefit was also verified in the combined treatment group for all other HD symptoms (pain at rest, 
pain at defecation and prolapse).
Conclusion: A combined treatment approach with MPFF and RBL significantly reduced the intensity of bleeding during 
the first month and the pruritus during the first week. 
Keywords: Hemorrhoids; Ligation; Flavonoids; Symptoms
INTRODUCTION
Hemorrhoidal disease (HD) results from the distal displacement 
of the anal cushions. The estimated prevalence of HD varies 
widely among several studies, with numbers from 4.4% to 40% 
being quoted [1]. The prevalence is higher among the Caucasian 
population, and the peak incidence tends to occur between the 
ages of 45 and 65 years [1-3]. The development of HD occurs 
when vascular, inflammatory and mechanical factors interact in a 
pathological way not fully understood so far [2-4]. Several risk 
factors for the development of HD are described. Constipation is 
frequently associated with HD probably because of the chronic 
straining, as are inadequate fiber intake and prolonged lavatory 
sitting [3-5]. However, some studies failed to demonstrate any 
correlation between chronic constipation and HD, and others 
demonstrated that diarrhea may also lead to HD, possibly due to 
the increased resting anal pressure required to maintain fecal con-
tinence [6, 7]. Overweight and certain professions, such as those 
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involving heavy labor, have also been reported to be associated 
with the disease [6, 8]. Lifestyle factors, such as smoking, alcohol 
intake and excessive coffee consumption, are also often impli-
cated, but reported data are inconsistent [2, 8]. The most com-
mon symptom of HD is painless rectal bleeding associated with 
bowel movement [1, 3]. Other signs and symptoms include hem-
orrhoidal prolapse, anal swelling, anal pain, discomfort, discharge, 
soiling and pruritus [2].  
The therapeutic strategy for treating patients with HD can range 
from dietary and lifestyle modification to medical treatment and 
even to surgery, according to the severity of the symptoms and the 
degree of the HD [9, 10]. Lifestyle modifications should be advised 
to patients with any degree of hemorrhoids [2, 10, 11]. The conser-
vative strategy recommended for first- and second-degree hemor-
rhoids includes pharmacological oral treatment that comprises 
phlebotonic agents [12, 13]. Daflon (Les Laboratoires Servier, 
Suresnes, France), the most studied phlebotonic agent, is a micron-
ized purified flavonoid fraction (MPFF) composed of 90% mi-
cronized diosmin and 10% flavonoids—hesperidin. This phlebo-
tropic drug increases venous tone, reduces stasis, inhibits inflam-
matory mediators and enhances lymphatic drainage [12, 13]. Re-
garding the instrumental therapies for early symptomatic hemor-
rhoids, rubber band ligation (RBL) is the most efficient and com-
monly used strategy [14, 15]. Other instrumental techniques are 
sclerotherapy, cryotherapy, infrared coagulation, laser therapy, and 
diathermy coagulation [9, 10]. HD may not respond to nonsurgi-
cal therapies, or patients may not accept or tolerate office proce-
dures. Surgical treatments can be an option in these settings and 
should also be considered the first choice of treatment for patients 
with large symptomatic third- and fourth-degree hemorrhoids [3, 
9]. Fig. 1 shows the Goligher’s classification of HD, as well as the 
therapeutic options available for each grade of HD [1, 2]. 
The most popular nonsurgical treatments are MPFF and RBL. 
Both, alone or combined, can be applied to patients with first- to 
third-degree hemorrhoids, according to the gastroenterologist 
personal criteria. To our knowledge, no studies have investigated 
the efficacy of MPFF and RBL together. A study with 351 patients 
compared the efficacy of infrared coagulation plus MPFF versus 
each treatment used alone and confirmed a favorable effect of 
MPFF as an adjunctive therapy to infrared coagulation in terms 
of bleeding [16]. Other studies evaluated the effect of MPFF after 
a hemorrhoidectomy and found favorable results. Ho et al. [17] 
showed a decreased risk of secondary bleeding after postoperative 
MPFF treatment. Colak et al. [18] reported that MPFF reduced 
the severity of pain in a study of 112 surgical patients. La Torre 
and Nicolai [19] showed a reduction in pain, tenesmus, pruritus 
and bleeding after postoperative MPFF treatment in 50 surgical 
patients. Our aim is to compare the efficacy of the most frequently 
nonsurgical strategies used either alone or in a combined ap-
proach in an ambulatory setting. 
METHODS
This longitudinal cohort study took place between May and No-
vember 2017 in the Gastroenterology Department of Braga Hos-
pital. The study was performed in accordance with the Declara-
tion of Helsinki and was approved by the Ethics Committees of 
Braga Hospital and Life and Health Sciences. All participants pro-
vided signed written informed consent. Anonymity and confi-
dentiality of the clinical data collected were granted in this study. 
Outpatients who underwent systemic medical and/or instru-
mental treatment during a proctology appointment at the Gastro-
enterology Department of Braga Hospital were invited to partici-
pate in the study. Patients over 18 years of age with HD (grades I, 
II, or III) who presented with rectal bleeding, pruritus, pain or 
prolapse and who underwent conservative treatment—systemic 
Fig. 1. Current treatment of internal hemorrhoids based on the degree of prolapse. RBL, rubber band ligation; IRC, infrared coagulation.
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medical and/or instrumental—were included in this study. Pa-
tients who were being treated with topical medication, who had 
HD grade IV, concomitant colonic or anorectal diseases, who had 
a history of pelvic radiation or colorectal cancer, and who were 
unable to provide informed consent were excluded. Sociodemo-
graphic characteristics, including age, sex, body mass index (BMI, 
defined as underweight <18.5 kg/m2, normal weight from 
18.5‒24.9 kg/m2, overweight from 25‒29.9 kg/m2, and obese >30 
kg/m2), current medication, eating habits, and bowel habits, were 
recorded. To evaluate the eating habits, we adapted the Mediter-
ranean Diet Pyramid and formulated a diet questionnaire [20]. 
Based on the number of “yes” answers, we classified the patients’ 
diets as healthy (5 or more yes answers), average (3 to 4 yes an-
swers), or poor (0 to 2 yes answers). To evaluate the prevalence of 
constipation, we used the Rome IV criteria [21]. 
Symptoms and signs of HD were recorded using the Sodergren 
score, a validated symptom severity scoring system [22]. Patients 
were asked to self-assess the severity of pruritus, the pain at rest 
and the pain during defecation throughout the last month ac-
cording to a scale from 0 to 5 (0, no symptoms to 5, severe symp-
toms). The frequency of prolapse was also reported according to a 
frequency scale (0, none; 1, less than once a month; 2, more than 
once a month; 3, more than once a week; 4, every day). Because 
bleeding is not considered in the Sodergren score, it was assessed 
separately using a similar scale from 0 (no symptoms) to 5 (severe 
symptoms). To assess the overall severity of the HD, we created a 
Global Symptom score ranging from 0 to 24, which included 
bleeding and the described subitems from the Sodergren score. 
The Global Symptom score was calculated by adding up the mean 
score of each symptom (Table 1). 
The durations and the types of previous treatments for HD were 
also recorded, as were the results of anoscopic examinations and 
the treatment strategies decided during the proctology appoint-
ments by the gastroenterologist specialists. The most frequently 
applied strategies defined our comparative groups: patients in the 
MPFF alone group (MPFF group) were prescribed Daflon 500 
mg (MPFF) for 7 days at a dose of 3 tablets twice per day for the 
first 3 days, followed by 2 tablets twice per day from day 4 to day 7. 
Patients in the RBL group underwent RBL; the ShortShot Saeed 
Hemorrhoidal Multi-Band Ligator with TriView Anoscope from 
Cook Medical (Bloomington, IN, USA) is the equipment used in 
Braga Hospital for RBL. The patients in the combined strategy 
group (RBL+MPFF group) first underwent RBL, after which Da-
flon 500 mg (MPFF) was prescribed for 7 days (at the same doses 
described above).
On day 7 (T7) and on day 28 (T28), a telephone interview was 
performed to reevaluate the hemorrhoidal symptoms by using the 
same scoring procedure as was applied at T0. Three time-intervals 
were defined to evaluate the evolutions of the symptoms and to 
compare the mean symptom score differences: the initial time 
from T0 to T7 = T0-7, the second time from T7 to T28 = T7-28, and 
the total time = T0-28. The Global Symptom score was calculated at 
T7 and T28 to compare the overall improvement of the HD in each 
group. 
Analyses were conducted with IBM SPSS Statistics ver. 22.0 
(IBM Co., Armonk, NY, USA). For quantitative variables with 
symmetric distributions, results were presented as means and 
standard deviations; for categorical variables, frequencies and per-
centages were calculated. The normality assumption was verified 
using the Shapiro-Wilk test. A t-test for independent samples was 
used to compare quantitative variables, and chi-square or Fisher 
exact test was used for categorical variables. A mixed between-
within subjects analysis of variance was used to compare the 
symptoms scores in the treatment groups along the 3 time points 
(T0, T7, and T28), considering the interaction effect of the type of 
treatment, and to compare symptom scores between treatments 
for each period of assessment. The Greenhouse-Geisser correc-
tion was used to calculate the P-value when variance homogene-
ity was not ensured (evaluation by Levene test for equality of vari-
ances). Statistical significance was considered for P < 0.05. 
RESULTS
The study population included 54 patients, of which 8 patients 
were excluded for having at least one exclusion criterion. In addi-
tion, only 2 patients underwent systemic medical treatment alone 
(MPFF group), so we excluded them as statistical analyses could 
not be performed with such a small group. Therefore, only 2 of 
the 3 treatment groups described above, the RBL+MPFF group 
with 19 patients and the RBL group with 25 patients for a total of 
44 patients were included in this study. No patients were lost to 
follow-up. The demographic characteristics of the study popula-
tion are described in Table 2. Eighteen participants (40.9%) were 
male and 26 (59.1%) were female, and the mean age of the partici-
pants was 58.4±11.5 years. The majority of patients were over-
weight (45.5%) or obese (34.1%), with a mean BMI of 28.1±4.4 
kg/m2. In terms of eating habits, 22 patients (50%) described a 
healthy diet, 19 (43.2%) an average diet and 3 (6.8%) a poor diet. 
Seventeen patients (38.6%) were constipated and 5 (11.4%) took 
laxatives often. Twenty-four patients (55.8%) took medication (at 
least one class) associated with constipation (iron supplements, 
calcium supplements, antidepressants, antihistamines, beta block-
ers, or proton-pump inhibitors). No statistically significant differ-
ences were found between the 2 groups (P > 0.05). A total of 8 pa-
Table 1. Patients’ clinical characteristics
Symptom Total score (0–24 points)
Pruritus (0–5 points)
Pain at rest (0–5 points)
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Age (yr) 58.4±11.5 56.6±14.6 59.8±8.5 0.41
Sex 0.45
   Male 18 (40.9) 9 (47.4) 9 (36.0)
   Female 26 (59.1) 10 (52.6) 16 (64.0)
BMI (kg/m2) 28.12±4.37 27.53±3.95 28.56±4.71 0.45
BMI 0.67
   Underweight 0 (0) 0 (0) 0 (0)
   Normal weight  9 (20.5)  3 (15.8)  6 (24.0)
   Overweight 20 (45.5) 10 (52.6) 10 (40.0)
   Obese 15 (34.1)  6 (31.6)  9 (36.0)
Diet 0.45
   Poor  3 (6.8) 0 (0)  3 (12.0)
   Average 19 (43.2) 9 (47.4) 10 (40.0)
   Healthy 22 (50.0) 10 (52.6) 12 (48.0)
Constipation 0.14
   No 27 (61.4) 14 (73.7) 13 (52.0)
   Yes 17 (38.6)  5 (26.3) 12 (48.0)
Use of laxatives 1.00
   No 39 (88.6) 17 (89.5) 22 (88.0)  




   No 19 (44.2)  8 (42.1) 12 (48.0)  
   Yes 24 (55.8) 11 (57.9) 13 (52.0)
Values are presented as mean±standard deviation or number (%).
RBL, rubber band ligation; MPFF, micronized purified flavonoid fraction; BMI, body 
mass index.











   I 8 (18.2) 5 (26.3) 3 (12.0)
   II 32 (72.7) 12 (63.2) 20 (80.0)  
   III 4 (9.1) 2 (10.5) 2 (8.0)
Duration of symptoms (mo) 0.76
   <6 1 (2.3) 1 (5.3) 0 (0)
   6–12 3 (6.8) 1 (5.3) 2 (8.0)
   >12 40 (90.9) 17 (89.5) 23 (92.0)
Previous treatment 0.85
   No treatment 34 (77.3) 14 (73.7) 20 (80.0)  
   Topic 8 (18.2) 4 (21.1) 4 (16.0)
   MPFF 0 (0) 0 (0) 0 (0)
   Surgery 2 (4.5) 1 (5.3) 1 (4.0)
Values are presented as number (%).
HD, hemorrhoidal disease; RBL, rubber band ligation; MPFF, micronized purified 
flavonoid fraction.





RBL+MPFF RBL P-value RBL+MPFF RBL P-value RBL+MPFF RBL P-value
Global score 0.14 11.21±4.66 10.72±4.59 0.73 4.68±4.83 5.88±4.12 0.38 3.05±4.30 4.72±4.37 0.21
Bleeding 0.15 3.05±1.54 3.56±1.53 0.28 0.37±0.76 1.68±1.35 0.001 0.21±0.42 1.28±1.34 0.002
Pruritus 0.03 2.53±1.58 1.56±1.83 0.07 1.21±1.51 1.08±1.38 0.77 0.74±1.28 0.80±1.38 0.88
Pain at rest 0.79 1.16±1.50 1.16±1.82 0.10 0.63±1.26 0.60±1.08 0.93 0.37±1.16 0.56±1.08 0.58
Pain at defecation 0.25 1.89±1.79 1.88±2.09 0.98 1.21±1.47 0.92±1,35 0.51 0.53±1.31 0.96±1.37 0.30
Prolapse 0.57 2.58±1.54 2.56±1.39 0.97 1.26±1.73 1.60±1.58 0.51 1.21±1.65 1.12±1.54 0.85
Values are presented as score or mean±standard deviation.
RBL, rubber band ligation; MPFF, micronized purified flavonoid fraction.
tients (18.2%) presented with grade I hemorrhoids, 32 patients 
(72.7%) with grade II hemorrhoids, and 4 patients (9.1%) with 
grade III hemorrhoids. Most patients (90.9%) had had HD for 
more than 12 months, and 10 patients (22.7%) had undergone 
previous treatment. No statistically significant differences regard-
ing the HD at baseline (Tables 3, 4) were found between the 2 
groups. Differences in the evolutions of the symptoms and the 
signs between groups in terms of scoring are presented in Table 4. 
Mean symptom score differences between the 3 time points for 
each treatment are presented in Table 5. 
Analysis of the Global Symptom score showed an overall im-
provement of HD symptoms in both groups during the study pe-
riod (T0-28; P < 0.001). This effect was noticed immediately during 
the first week (T0-7), with a significant mean score reduction being 
observed in both treatment groups (P < 0.001). A comparison of 
the 2 strategies showed a trend in favor of the combined treat-
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Table 5. Mean symptom score differences between T0 and T7 (T0-7), T7 and T28 (T7-28), and T0 and T28 (T0-28) according to treatment group
Symptom
RBL+MPFF RBL
T0-7 T7-28 T0-28 T0-7 T7-28 T0-28
Global score
   Mean difference 6.526 1.632 8.158 4.840 1.160 6.000
   P-value <0.001 0.03 <0.001 <0.001 0.07 <0.001
Bleeding
   Mean difference 2.684 0.158 2.842 1.880 0.400 2.280
   P-value <0.001 0.45 <0.001 <0.001 0.03 <0.001
Pruritus
   Mean difference 1.316 0.474 1.789 0.480 0.280 0.760
   P-value <0.001 0.05 <0.001 0.07 0.17 0.02
Pain at rest
   Mean difference 0.526 0.263 0.789 0.560 0.040 0.600
   P-value 0.11 0.24 0.02 0.05 0.84 0.04
Pain at defecation
   Mean difference 0.684 0.684 1.368 0.960 –0.04 0.920
   P-value 0.07 0.007 <0.001 0.004 0.85 0.005
Prolapse
   Mean difference 1.316 0.053 1.368 0.960 0.480 1.440
   P-value <0.001 0.87 0.001 0.003 0.09 <0.001
RBL, rubber band ligation; MPFF, micronized purified flavonoid fraction.
Fig. 2. Evolution of the Global Symptom mean score during the 
study period in each treatment. RBL, rubber band ligation; MPFF, 
micronized purified flavonoid fraction.
Fig. 3. Evolution of bleeding mean score during the study period for 
each treatment. RBL, rubber band ligation; MPFF, micronized puri-
fied flavonoid fraction.
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2). Both treatments showed a significant improvement in bleed-
ing during the first week (T0-7), which was sustained over the total 
time (T0-28) (P < 0.001). A comparison of the 2 types of interven-
tion (Fig. 3) showed in the RBL+MPFF group the decreases in the 
bleeding mean scores at T7 (P = 0.001) and T28 (P = 0.002) were 
significantly different from those in the RBL group (P = 0.003). 
Both treatment groups showed a significant reduction in pruritus 
intensity over the total time (T0-28; P < 0.01). During the first week 
(T0-7), the combined treatment group showed a greater reduction 
(P < 0.001) than the RBL treatment group (P = 0.07). The evolu-
tion curve of the pruritus mean score reduction in Fig. 4 is signifi-
cantly better for the combined treatment group (P = 0.03). Re-
garding the other parameters—pain at rest, pain at defecation, 
and prolapse—no substantial improvements were observed in ei-
ther of the 2 groups at any time during the treatment (T0-28; P < 
0.05). A comparison of the 2 types of intervention showed no dif-
ferences in the mean score between the 2 groups for pain at rest at 
T7 (P = 0.93) and at T28 (P = 0.58), but that comparison showed 
significant mean score reductions for pain at defecation in the 
RBL group during the first week (T0-7; P = 0.004) and a marginally 
significant reduction for the RBL+MPFF group (P = 0.07). Dur-
ing the following weeks (T7-28), only the patients in the combined 
treatment group maintained a sustained improvement (P = 
0.007). For prolapse, the comparison of both strategies showed no 
differences in the mean score reductions between the groups at T7 
(P = 0.51) and T28 (P = 0.85). 
Nine patients (20.5%) described secondary effects after the RBL 
procedure. Mild pain, which was reported by 7 patients (15.9%) 
during the first 3 days, was the most common complication. This 
was followed by secondary haemorrhage, which was reported by 
2 patients (4.5%) about 2 weeks after banding. 
DISCUSSION
Several nonsurgical options can be used to treat patients with HD. 
We decided to evaluate the systemic medical treatment and the 
instrumental treatment because the focus of our interest was the 
conservative treatment of patients with HD during a proctologi-
cal consultation in a hospital setting. In the Primary Care System, 
lifestyle modifications and topical medical treatments are consid-
ered everyday standard-of-care treatments for patients with HD. 
RBL is the instrumental treatment used at Braga Hospital, and 
several studies have confirmed its superiority over other instru-
mental methods [9, 10]. Some clinicians choose to combine 
MPFF with RBL, based on the pharmacological effect of flavo-
noids in reducing HD symptoms and their experience with the 
drug. Accordingly, 2 treatment groups were eligible for evalua-
tion—the RBL alone group and the combined RBL+MPFF group. 
Not enough patients (only 2) were available to create a third treat-
ment group of medical treatment (MPFF) alone. 
Regarding the demographic characteristics of our study popula-
tion, the mean age of our patients was 58 years, and the propor-
tion of males to females 1.4:1, which is in accordance with what is 
described in the current literature [8]. Our results support exces-
sive weight as a risk factor for HD because most of our patients 
were overweight, having a mean BMI of 28 kg/m2 [6]. In our 
study, 61% of the patients did not report constipation, calling into 
question the impact of this condition as a risk factor for HD. In 
our study population, 50% of our patients reported a healthy 
Mediterranean diet while only 6.8% reported a poor diet. These 
results question the influence of a healthy diet in the prevention 
of HD. However, our patients may have overestimated the quali-
ties of their diets and reported healthier diets than they truly had; 
the fact that the majority of our patients were overweight supports 
this supposition.
The Global Symptom score showed an overall improvement of 
HD for both treatments throughout the study period, with a trend 
showing a benefit for adding MPFF to RBL. Regarding bleeding, 
patients treated with the combined treatment showed higher clin-
ical benefit in comparison to RBL alone both in the immediate 
follow-up (first week) and afterwards (1 month later). This may 
be attributed to MPFF’s protective effect against capillary fragility. 
Regarding pruritus, during the first week and throughout the fol-
low-up time, the addition of MPFF to RBL had a greater impact 
in reducing the severity of this symptom. This suggests that MPFF 
may be beneficial in the acute setting of more pruritic HD. In 
terms of pain at rest and at defecation, although both treatments 
were effective at reducing the symptoms, in the second-time in-
terval (T7-28), a trend was seen that favored the combined treat-
ment. Perhaps the reduction in pain at defecation was more pro-
Fig. 4. Evolution of pruritus mean score during the study period for 
each treatment. RBL, rubber band ligation; MPFF, micronized puri-
fied flavonoid fraction.
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nounced in the RBL alone group in the first week because of the 
promptest relief associated with the isolated fall of the elastics 
without the steady anti-inflammatory effect of the MPFF. The 
anti-inflammatory effect of MPFF in the combined treatment 
group probably makes the reduction in the pain at defecation less 
pronounced but more sustained over time. Regarding prolapse, 
although the combined treatment showed a steeper symptomatic 
decrease during the first week, no significant differences between 
the 2 treatments were seen at the end of the evaluation. No unex-
pected complications after RBL were described, and our results 
are in accordance with those in the literature [15]. 
Some limitations were identified in our study. First, our sample 
size was small, which limits the extrapolation of our results. 
Moreover, our study was designed as a longitudinal cohort study, 
differing from other studies which involved randomized con-
trolled trials. A multicenter study, with a larger patient population 
and randomization, could highlight our results. Second, our re-
evaluation was based on a subjective assessment of HD symp-
toms, which was performed by telephone interview. 
According to our study, MPFF as an adjunctive therapy to RBL 
has a clinical benefit in the treatment of patients with hemorrhoid 
disease. A 7-day treatment with MPFF after RBL significantly re-
duced the intensity of bleeding during the first month. Addition-
ally, the combined treatment showed a favorable effect in that it 
reduced pruritus in an acute setting. This combined treatment 
showed a trend of being clinically beneficial for reducing the se-
verity of all HD symptoms, but verification of this finding 
through a study with a larger sample size would be important to 
strengthen our results.
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